portion of the adult population and has become a significant public health problem, because it is also associated with endstage renal disease, cardiovascular disease, and premature death. 1 Cardiovascular risk factors such as dyslipidemia and hypertension (HTN) may lead to deterioration of renal function and have been associated with CKD, progressive atherosclerosis, and cardiac morbidity. Furthermore, clustering of HTN and hypercholesterolemia (HC) 2 further increases the risk for cardiovascular 3, 4 and renal 5, 6 disease.
Cardiovascular risk factors influence renal function and structure by complex neural, humoral, and mechanical mechanisms. An increase in systemic blood pressure results in glomerular capillary wall stretch, endothelial damage, and upregulation of stretch-sensitive enzymes. 7 This mechanism and elevated serum cholesterol levels increase oxidative stress and elicit vascular endothelial dysfunction, which may in turn intensify renal cellular injury, apoptosis (programmed cell death), and interstitial fibrosis. 8 We have previously shown that early renovascular HTN is associated with increased oxidative stress, 9, 10 upregula-tion of inflammatory and profibrotic factors, with impairment of renal hemodynamics, function, and responses to challenge, and that the coexistence of HTN with HC (HTC) amplifies renal dysfunction and oxidative stress. 11 An important defense mechanism to offset tissue destruction involves recruitment of progenitor and stem cells to the injury site to regenerate and replace damaged cells. Endothelial cells play a key role in renal recovery, because viable endothelium is essential for the survival of mesangial and tubular cells by virtue of its role in oxygen and nutrient delivery. 12 Indeed, renal repair may be attributed to both migration and proliferation of resident endothelial cells, as well as recruitment of circulating endothelial progenitor cells (EPC) 13 driven by homing signals such as stem cell factor (SCF), 14 stromal cell-derived factor-1 (SDF-1), 15 and uric acid 16 released by the injured tissue. Furthermore, we have demonstrated the important contribution of exogenous autologous EPC to repairing the stenotic kidney in HTN. 17 However, a noxious microenvironment characterized by oxidative stress, inflammation, and endothelial dysfunction due to exposure to cardiovascular risk factors might induce apoptosis and decrease the survival of recruited cells, and thus interfere with renal regeneration.
The cholesterol-lowering drugs 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) exert profound pleiotropic antiinflammatory, antiproliferative, and immunomodulatory actions, which may partly account for their beneficial effects on renal function and structure in experimental models of renal disease. 18 -20 Furthermore, atorvastatin has recently been shown to improve the myocardial microenvironment and facilitate mesenchymal stem cell survival and differentiation during acute infarction and reperfusion. 21 However, the extent of EPC recruitment or fate in the kidney during exposure to HTC and the efficacy of statins to improve renal repair have not been fully explored.
Therefore, the current study was designed to test the hypothesis that simvastatin improves the survival of EPC in the renal microenvironment imposed by HTC, in association with improved renal function and fibrosis.
Methods
The Mayo Clinic Institutional Animal Care and Use Committee approved the procedures. Seventeen domestic pigs were studied after 12 weeks of observation. Eleven pigs (50 to 60 kg) were studied 12 weeks after induction of unilateral renal artery stenosis and renovascular HTN, which was accompanied by a high-cholesterol diet of 2% cholesterol and 15% lard (TD-93296, Harlan-Teklad) 22 initiated on the same day. Renal artery stenosis was induced by coil implantation in the renal artery, which leads to development of HTN within 5 to 10 days. 10, 23, 24 Of these 11 pigs, 5 also received chronic supplementation with simvastatin (1.2 mg/kg per day, HTCϩS) at a dosage that is used clinically (up to 80 mg/day) but has lower efficacy and does not decrease lipid levels in pigs. 23, 25 Six age-matched untreated pigs served as normal controls. As we have done before, we secured a telemetry catheter in the femoral artery for monitoring daily blood pressure until the end of the study. 10, 19, 23, 24 After 12 weeks of observation, in vivo electron beam computed tomography studies were performed for assessment of basal renal blood flow (RBF) and glomerular filtration rate (GFR) of the nonstenotic kidney, and they were repeated during suprarenal infusion of acetylcholine (Ach) to assess endothelial function. 19 Blood samples were collected from the inferior vena cava for measurement of lipid profile (Roche Laboratories, Basel, Switzerland), creatinine (in the clinical laboratory), circulating oxidized low-density lipoprotein (ox-LDL) (Mercodia, Uppsala, Sweden), and plasma renin activity (radioimmunoassay) and from the renal vein of the HTC or normal kidney for measurement of plasma concentration of basic fibroblast growth factor (bFGF) using enzyme immunoassay, 26 as described previously. 27 EPC homing signals were assessed by SCF and uric acid levels in the renal vein, as well as SDF-1 expression in the kidney. Urine samples were collected at the end of the study using a suprapubic puncture, and protein concentration was determined as described previously. 17 After completion of all studies, the pigs were euthanized with a lethal injection of Sleepaway (100 mg/kg intravenously; Ft Dodge Laboratories, Inc, Ft Dodge, Iowa). Kidneys were removed using a retroperitoneal incision and immediately dissected, and sections were shock-frozen in liquid nitrogen (and maintained at Ϫ80°C) or preserved in formalin. 24 Fixed blocks of tissue were embedded in paraffin, and 5-m-thick sections were cut from each block. Capillaries were manually counted using hematoxylin/eosin staining, as described previously. 23 Furthermore, kidney sections were stained for angiomodulin, a protein that is often upregulated in angiogenesis. 28 Harvested renal tissue (cortex and medulla) was then used for in vitro studies. Renal EPC recruitment was evaluated by double immunostaining of CD34 with vascular endothelial growth factor (VEGF), KDR (VEGF receptor-2), or tumor necrosis factor-␣ (TNF-␣) to test for EPC phenotype and paracrine function. Apoptosis was evaluated by the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay, activated caspase-3 staining, and protein expression of the proapoptotic apoptosis-inducible factor and antiapoptotic Bcl-xL. To identify the apoptotic cells, concurrent TUNEL and staining for macrophage, fibroblast, tubular cell (cytokeratin), renal resident stem cell (Oct-4), or EPC markers were performed. To assess the renal microenvironment, oxidative stress was evaluated by the expression of the NADPH oxidase (p47phox and p67phox subunits) and in situ production of superoxide anion detected by fluorescence microscopy using dihydroethidium, as previously described. 29 Renal inflammation was evaluated by expression of mononuclear chemoattractant protein and macrophage infiltration. Fibrosis was assessed by trichrome staining of kidney tissue and by bFGF levels in the renal vein. For details, see the online supplement, available at http://atvb.ahajournals.org.
To explore the possible mechanisms involved in the effects of simvastatin on EPC, peripheral blood was also collected from HTC pigs for isolation and culture of EPC, using a standard protocol as we described previously. 17 EPC were then exposed to the proapoptotic factor ox-LDL or TNF-␣, cocultured with or without simvastatin, and EPC apoptosis, proliferation, and migration were evaluated. The expression of CHOP, a protein that mediates endoplasmic reticulum stressinduced apoptosis, 30 was also assessed. For details, see the online supplement.
Statistical Analysis
Results are expressed as meanϮSEM. Comparisons within groups were performed using the paired Student t test and among groups using ANOVA, followed by the Tukey test. Statistical significance for all tests was judged at PϽ0.05.
Results

General Group Characteristics
Mean arterial pressure, total cholesterol, and low-density lipoprotein cholesterol were all significantly and similarly increased in HTC and HTCϩS compared with normal (Table) . Plasma creatinine and urine protein levels remained similar among the groups (Table) . Renal vascular resistance was increased in HTC and slightly attenuated in the HTCϩS group, whereas plasma renin activity was not different among the groups (Table) .
Renal Hemodynamics and Function
Basal renal volume, RBF, and GFR were all significantly elevated in HTC and HTCϩS compared with normal. However, the increase of RBF and GFR from baseline in response to Ach was significantly blunted in HTC compared with normal, and it was improved in HTCϩS ( Figure 1 ).
HTC Induces Oxidative Stress and Inflammation, Which are Attenuated by Simvastatin
Ox-LDL was elevated in the HTC group but reduced (although not normalized) in HTCϩS (Table) . Dihydroethidium staining showed an increased abundance of superoxide anion in HTC compared with normal (7.4Ϯ1.6% versus 1.8Ϯ0.8%, PϽ0.05); this increase was attenuated by simvastatin (to 2.6Ϯ0.4%, PϽ0.05 versus HTC) ( Figure 2 ). The expression of p47 (NAD(P)H oxidase subunit) was also upregulated in HTC and normalized by simvastatin, although p67 remained elevated in HTCϩS kidneys ( Figure 2 ). The expression of mononuclear chemoattractant protein, an important regulator of macrophage recruitment, was also increased in HTC and normalized in HTCϩS (Figure 3 ), suggesting decreased inflammation by simvastatin. Furthermore, the number of interstitial macrophages was significantly increased in HTC compared with normal (12.3Ϯ1.3 versus 1.0Ϯ0.2 per field, PϽ0.001), but it was significantly decreased by simvastatin (2.7Ϯ0.8 per field, PϽ0.05 versus HTC, Pϭ0.09 versus normal) ( Figure 3 ).
HTC Elicits EPC Apoptosis, Which Is Blunted by Simvastatin
The number of renal CD34ϩ/KDRϩ cells was increased in both HTC and HTCϩS compared with normal kidneys, suggesting recruitment of circulating EPC (Figure 4 ). The CD34ϩ cells were concentrated mostly in the medullary area. Importantly, CD34ϩ cells were observed adjacent to increased expression of both VEGF and TNF-␣ in HTC (Supplemental Figure I) . Interestingly, simvastatin further increased VEGF expression but had no effect on TNF-␣ (Supplemental Figure I) . In addition, SDF-1 expression increased in both HTC and HTCϩS kidneys, whereas the increased renal vein levels of the homing signals SCF and uric acid in HTC returned to normal level in HTCϩS (Figure 4 , Table) . The number of TUNELϩ and caspase-3ϩ
apoptotic cells was increased in HTC compared with normal kidneys; this increase was observed mainly in the medullary tubulointerstitial compartment, but it was significantly decreased by simvastatin ( Figure 5 ), suggesting blunted apoptosis. Interstitial TUNELϩ cells did not costain with either macrophage (CD163), fibroblast (vimentin and smooth muscle actin; data not shown), or resident stem cell (Oct-4) markers, and very few coexpressed cytokeratin (Supplemental Figure II) , but many costained with CD34 ( Figure 5 ). Indeed, the number of CD34ϩ/ TUNELϩ cells increased in HTC, suggesting EPC apoptosis, which was attenuated by simvastatin ( Figure 5 ). The number of Oct-4ϩ cells was unchanged in HTC compared with normal (0.08Ϯ0.02% versus 0.06Ϯ0.02%, PϾ0.05) and was unaffected by simvastatin (0.08Ϯ0.03%), and they did not costain with TUNEL, indicating that resident stem cells may not be involved in renal fibrosis in HTC. The expression of the proapoptotic factor apoptosis-inducible factor remained unchanged among the groups, but that of the apoptosis inhibitor Bcl-xL was decreased in HTC and increased in HTCϩS (Figure 3 ). Histological analysis showed that capillary density was decreased in HTC compared with normal and improved in HTCϩS kidneys (Supplemental Figure III) . Furthermore, angiomodulin expression was also downregulated in HTC and improved by simvastatin, indicating that angiogenic activity was impaired in HTC and improved by simvastatin (Supplemental Figure III ).
Simvastatin Directly Attenuates EPC Apoptosis In Vitro
Studies in isolated EPC showed that simvastatin significantly decreased ox-LDL-induced apoptosis in these cells, an effect that was inhibited by mevalonate. These data indicate that simvastatin directly reduced EPC apoptosis. Simvastatin achieved an antiapoptotic effect similar to that of tempol to attenuate ox-LDL-induced EPC apoptosis, but it showed less efficacy to prevent TNF-␣-induced EPC apoptosis (Pϭ0.07 versus TNF-␣ alone, Supplemental Figure IV) . Interestingly, simvastatin downregulated the expression of CHOP, an important apoptosis-regulating protein, under conditions of endoplasmic reticulum stress. Thus, the antioxidant property of simvastatin may contribute more than its antiinflammation property to decrease apoptosis in EPC. Ox-LDL also impaired EPC migra- tion and proliferation, both of which were normalized by simvastatin (Supplemental Figure II) .
HTC Induces Renal Fibrosis, Which Is Attenuated by Simvastatin
The levels of bFGF renal vein plasma were elevated in HTC compared with normal kidney, and they were normalized by simvastatin (Table) . Renal trichrome staining showed increased interstitial and perivascular fibrosis in HTC compared with normal kidney (3.8Ϯ0.5% versus 0.36Ϯ0.05%, Pϭ0.001), and it was attenuated in HTCϩS kidneys (1.3Ϯ0.1%, Pϭ0.005, versus HTC and normal, Figure 2 ). Minimal tubular atrophy was observed in HTC animals, but no glomerulosclerosis or tubular epithelial cells expressing vimentin or ␣-smooth muscle actin (data not shown) were observed in any group.
Discussion
This study shows that HTC in swine is associated with recruitment of EPC to the kidney, but at the same time, it is associated with increased EPC apoptosis, possibly because of renal endothelial dysfunction, oxidative stress, and inflammation, which are associated with renal interstitial fibrosis. Chronic simvastatin supplementation improved the renal microenvironment and decreased apoptosis, suggesting improved EPC survival. These pleiotropic effects were conferred without affecting blood pressure, cholesterol levels, or basal renal function, suggesting a role for simvastatin in protecting the kidney during exposure to concurrent HC and HTN, independent of systemic effects. Our in vitro data confirmed that simvastatin directly decreased ox-LDLinduced EPC apoptosis.
CKD has become an important public health concern in the United States and constitutes a risk factor for end-stage renal disease, cardiovascular and cerebrovascular disease, and premature death. 31 The evolution of CKD and its cardiovascular outcomes are accelerated and aggravated by clustering of risk factors, such as HTN and HC. Indeed, it has become clear that the most effective approach to preserve renal function and slow down the consequences of CKD is to identify and treat risk factors and renal injury at the early stage of CKD. 32 In our HTC model, renal injury was evoked by a short coexistence of HTN and HC, which are often observed in a clinical setting. HTN can injure endothelial, mesangial, tubular, and interstitial cells 12 and may cause local inflammation, 33 oxidative stress, 34 and fibroproliferative response. HC leads to deposition of oxidized lipids, decreased nitric oxide bioavailability, endothelial dysfunction, inflammation, and fibrosis. 35 Both oxidative stress and inflammation can evoke apoptosis of renal cells 36 and EPC. 37 Bone marrow-derived CD34ϩ EPC participate in tissue repair in many diseases, 17, 38, 39 and an imbalance of kidney damage and repair may lead to dysfunction and fibrosis of the affected kidney. Indeed, our study demonstrated that the pro-oxidant and inflammatory milieu induced by HTC is accompanied by apoptosis mainly of interstitial CD34ϩ/KDRϩ progenitor cells, presumably recruited to participate in kidney repair, thereby impairing renal self-regeneration potential. Notably, the HTC kidney also exhibited a small number of apoptotic tubular cells, but no apoptotic cells costaining with CD163, vimentin, ␣-smooth muscle actin, or Oct-4. Furthermore, the unchanged number of Oct-4ϩ cells in HTC animals indicates that resident stem cell may not be involved in renal fibrosis in HTC. Interestingly, the medulla recruited most of the EPC, and most EPC apoptosis was also observed in the medulla. The medulla of the kidney is considered perpetually hypoxic even under physiological conditions because of its unique circulation, 40 and it is vulnerable to insults. A previous study also suggested that acute renal ischemia induces tubular cell apoptosis and macrophage infiltration in the medulla. 41 It is not unlikely that similar susceptibility drives EPC recruitment to the noxious microenvironment secondary to hypertension and HC.
In HTC, administration of simvastatin may help the kidney restore the balance of injury and repair through several mechanisms. We have shown that simvastatin attenuated coronary 42 and renal 25 inflammation and oxidative stress, and improved endothelial function in HC. 42 This study extended our previous observations by showing a potential role for simvastatin in attenuating kidney injury by decreasing circulating ox-LDL, downregulating p47phox, and attenuating dihydroethidium staining in HTC pigs. Furthermore, simvastatin blunted the upregulated mononuclear chemoattractant protein expression and macrophage infiltration in HTC, suggesting decreased local inflammation.
It is pertinent that both decreased oxidative stress and inflammation may have contributed to blunt apoptosis of EPC participating in kidney repair. Our results show increases in both EPC (CD34/KDRϩ cells) and apoptotic EPC (TUNEL/ CD34ϩ) numbers in HTC, and they show that simvastatin decreased only TUNEL/CD34ϩ apoptotic cells, not overall EPC numbers, indicating that simvastatin decreased EPC apoptosis in HTC. We also found that SDF-1, a major EPC homing factor, was similarly increased in HTC and HTCϩS pigs. These may have resulted in a similar number of CD34ϩ cells in HTC and HTCϩS. It is possible that at this early stage of the disease, EPC recruitment signaling secondary to renal injury is still intact, yet the noxious microenvironment leads to their apoptosis and thereby decreases their availability. The observation that the number of EPC in the HTCϩS kidney was similar to that in HTC kidney, in the face of markedly decreased renal injury, may, in fact, imply that simvastatin increases EPC mobilization despite the decrease in renal damage.
The decreased expression of the antiapoptotic factor Bcl-xL and activation of caspase-3 in HTC might have facilitated EPC apoptosis, but the proapoptotic factor apoptosis-inducible factor remained unchanged among the groups, suggesting a direct role for additional mediators, such as increased oxidative stress and inflammation, in promoting EPC apoptosis in HTC. Our in vitro data also showed that ox-LDL increased in EPC expression of CHOP, a protein that mediates apoptosis induced by endoplasmic reticulum stress, 30, 43 implicating it in regulation of EPC apoptosis. These results agree with previous studies showing that cardiovascular risk factors elicit endoplasmic reticulum stress that can be ameliorated by statins. 44, 45 Simvastatin downregulated ox-LDL-induced CHOP expression in a mevalonateindependent manner, suggesting that it blunts endoplasmic reticulum stress via an alternative pathway. Furthermore, we found that simvastatin rescued EPC migration and proliferation that were attenuated by ox-LDL in vitro. The increased spatial association with VEGF in the HTCϩS kidney may imply improved EPC paracrine function as well, whereas cytokine expression (TNF-␣) was unaffected. Our findings are underscored by previous studies showing that statins promote differentiation of mononuclear cells to EPC in vitro, 46 enhance progenitor cell migration and proliferation, and downregulate EPC apoptosis in the ischemic hindlimb. 47 Simvastatin had no effect on apoptosis in untreated EPC, but it blunted ox-LDL-induced EPC apoptosis to an extent similar to the superoxide dismutase mimetic antioxidant tempol. On the other hand, it was less effective in preventing TNF-␣-induced EPC apoptosis. Thus, the antioxidant property of simvastatin may contribute more than its antiinflammation trait to attenuate EPC apoptosis. SDF-1, SCF, and uric acid may have signaled EPC homing to the kidney, because their levels were increased in the HTC kidney or vein. A decrease in renal vein SCF and uric acid by simvastatin may reflect blunted renal injury, as well as attenuated oxidative stress (because uric acid is a downstream product of xanthine oxidase).
In this study, simvastatin supplementation did not reduce the elevated blood pressure (the driving force of renal perfusion pressure), and the baseline function of the HTC kidney therefore remained greater than normal. Nevertheless, the elevated renal vascular resistance in HTC was slightly decreased with simvastatin, suggesting decreased microvascular tone. Importantly, simvastatin improved RBF and GFR response to Ach (reflecting improved endothelial function), possibly by increasing nitric oxide availability, an effect that may also contribute to dampening fibrosis. 48 Furthermore, impaired GFR responses to challenge may accompany and be an index of early tubular dysfunction, 10 which precedes alterations in traditional renal function indices (eg, plasma creatinine and urinary protein). Indeed, we have previously shown that functional impairment in GFR was associated not with glomerulosclerosis but with tubular dysfunction 10 and that tubular dysfunction preceded structural injury. 49 The improvement in the renal microenvironment (decreased inflammation and oxidative stress, improved endothelial function) and cellular survival and repair culminated in decreased fibrosis and attenuated renal injury.
Thus, simvastatin attenuated not only the structural but also the functional adverse effects of HTN and HC on the kidney. Because it lowered neither cholesterol levels nor blood pressure, this was likely a direct effect of the drug on pathogenic mechanisms within the kidney. Indeed, statins at high doses improve renal function in normocholesterolemic animal models, and we have shown their efficacy in the ischemic swine kidney. 19 The present study extends these observations and demonstrates new mechanisms for their capacity to protect the kidney exposed to a cluster of cardiovascular risk factors, using a large animal model and a clinically relevant dose, independent of lipid-or blood pressure-lowering properties.
Limitations
In the present study, simvastatin was administered as a preventive measure, and the pigs in our study were relatively young. It is not unlikely that additional mediators contribute to renal damage and repair during more severe and prolonged elevations in blood pressure or serum cholesterol, some of which may not be adequately blunted by statins. Additional studies are needed to examine the efficacy of simvastatin to reverse preestablished or long-duration renal damage, especially once glomerulosclerosis has developed. The drug is also less efficacious in pigs than in humans, and a higher dose is required to decrease cholesterol levels in this model, thus allowing demonstration of its pleiotropic effects. The effects of statins on blood pressure are inconsistent and were not observed in our study.
In summary, this study shows that at the early phase, the coexistence of cardiovascular risk factors HTN and HC impairs renal function and increases tissue oxidative stress and inflammation. Although this injury triggered EPC homing signals and recruitment, the noxious microenvironment led to their apoptosis, thereby perpetuating the imbalance of tissue damage and repair. Simvastatin improved the renal microenvironment and blunted EPC apoptosis and renal interstitial fibrosis. Our study suggests that simvastatin can modulate renal deterioration induced by HTN and HC and suggests a role for this drug in protecting the kidney.
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